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Introduction
Immune reconstitution inflammatory syndrome (IRIS) is 
one of the complications of antiretroviral therapy (ART) 
leading to morbidity in HIV-infected patients [1]. IRIS can 
occur with any opportunistic infection, and features two 
distinct forms: paradoxical IRIS, with paradoxical worsen-
ing of a known pre-existing infection; or unmasking IRIS, 
when a previously undiagnosed condition in HIV-infected 
patients is revealed with exaggerated local or systemic 
inflammation, soon after the commencement of ART [1].
Abstract There is a paucity of data on the immune recon-
stitution inflammatory syndrome (IRIS) in the Central Afri-
can region. We followed ART-naive HIV-infected patients 
initiating antiretroviral therapy in an HIV clinic in Gabon, 
for 6 months. Among 101 patients, IRIS was diagnosed in 
five. All IRIS cases were mucocutaneous manifestations. 
There were no cases of tuberculosis (TB) IRIS, but active 
TB (n = 20) was associated with developing other forms of 
IRIS (p = 0.02). Six patients died. The incidence of IRIS 
is low in Gabon, with mild, mucocutaneous manifestations.
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Although many studies have reported on IRIS incidence 
in a variety of epidemiologic settings [1], there is a pau-
city of published data on the incidence and risk factors of 
the syndrome in the Central African region [2]. Character-
istics of this setting differ from other regions of the world 
in several aspects, including a high burden of co-existing 
parasitic infections [3], a high genetic variability of HIV 
[4] and the equatorial latitude contributing to a decreased 
likelihood of vitamin D deficiency [5].
Despite the decrease of HIV-associated mortality since 
the implementation of ART, mortality remains high in 
certain patient groups, especially early after starting ART 
[6]. Tuberculosis (TB) is an important cause of early mor-
tality after ART initiation [6], even when patients receive 
treatment for both infections in line with international 
guidelines. The causes of this high mortality remain to be 
elucidated.
In this prospective study, we describe the incidence and 
risk factors for IRIS in Lambaréné, Gabon. Secondly, we 
determine mortality during the first 6 months after ART ini-
tiation and investigate associated risk factors.
Materials and methods
Recruitment for this prospective cohort study was per-
formed in Lambaréné, Gabon. The HIV seroprevalence is 
estimated at around 4.1% in Gabon [7]. Lambaréné is a 
town of 35,000 inhabitants situated within the Central Afri-
can rainforest area of the Moyen Ogooué province. Patients 
were recruited at the regional HIV clinic (Centre de Traite-
ment Ambulatoire). ART was initiated if patients had CD4 
counts less than 350 cells/µL or were symptomatic [World 
Health Organization (WHO) stage 3 or 4] [8], in accord-
ance with the Gabonese national guidelines. In patients co-
infected with TB, ART was initiated after the two-month 
intensive phase of TB treatment, or 2 weeks after TB treat-
ment initiation, if CD4 counts were less than 100 cells/µL.
Ethical clearance was obtained from the Institutional 
Review Board of the Centre de Recherches Médicales de 
Lambaréné (CERMEL). All participants provided written 
informed consent.
ART-naïve patients were followed for 6 months after 
they initiated ART. From February 2012 to November 
2013, all adult (≥18 years old) ART-naïve patients starting 
ART at the clinic were screened for eligibility. Exclusion 
criteria were pregnancy, history of ART and severe anemia 
(hemoglobin <6.0 g/dL, in view of repeated blood draws) 
(Fig. 1). Follow-up visits were performed at one, three and 
six months after patients started ART, with additional visits 
in case of new health complaints.
The estimated sample size was 100 patients, among 
which we expected to find 30 IRIS cases, based on 
previous research from epidemiologically comparable set-
tings [1]. As recruitment was challenging and slower than 
expected, the recruitment interval was prolonged from 12 
to 21 months.
Basic demographic data, World Health Organization 
staging [8] and medical history including previous illnesses 
and opportunistic infections were obtained at enrolment. 
An extensive physical exam was performed by one of the 
study physicians (SJ or KO), including a basic neurologic 
exam, visual acuity testing and a full inspection of the skin 
for cutaneous abnormalities. At follow-up visits, informa-
tion on any new health complaints and self-reported ART 
compliance was documented and the physical exam was 
repeated.
At enrolment and follow-up visits, full blood counts and 
basic chemistry tests were done at the CERMEL laboratory. 
Baseline hepatitis B serology HIV viral loads were meas-
ured, using the COBAS TaqMan 48 system (Roche Molec-
ular Systems Inc., Pleasanton, CA, USA). CD4 counts 
were acquired using a BD FACSCount™ system (Becton–
Dickinson, Franklin Lakes, NJ, USA). CD4 counts and 
HIV viral loads were measured at baseline, month 3 and 
month 6, and at the time of an IRIS event. Samples were 
transported to the Academic Medical Center, where the 
serum cryptococcal latex antigen test (CLAT) and serology 
for human T-cell lymphotropic virus 1 (HTLV-1) were per-
formed on enrolment serum samples.
All patients were evaluated for signs and symptoms of 
TB (cough, fever, night sweats and possible close contact 
with TB infected individuals). Baseline chest radiography 
was performed, and a Focused Assessment with Sonogra-
phy for HIV-associated TB (FASH), to increase diagnostic 
yield of the screening process [9]. FASH was performed in 
the context of an ongoing study and was not part of routine 
clinical care in Gabon. Sputum collection was attempted in 
all patients. Where possible, one spot sample and 2 morning 
sputa were sent for fluorescent microscopy using auramine-
rhodamine staining performed at CERMEL. Samples were 
sent for culture applying a previously described procedure 
[10]. In the instance of any TB symptoms at follow-up vis-
its, diagnostic procedures were repeated.
To diagnose ophthalmological manifestations of IRIS, 
we performed baseline retinal imaging and in case of a 
deterioration in visual acuity at follow-up visits using a 
PanOptic ophthalmoscope (Welch-Allyn, Skaneateles 
Falls, NY, USA). Images were captured on an iPhone 4 
(Apple Inc., Cupertino, CA, USA) and sent for inspection 
by an ophthalmologist specialized in HIV-related disorders 
at the VU Medical Center in the Netherlands (CM).
Enrolment and follow-up data were captured in an 
OpenClinica® database (Waltham, MA, USA).
Main outcomes for this study were development of 
IRIS and 6-month mortality. We used criteria of the 
Low incidence of the immune reconstitution inflammatory syndrome among HIV-infected patients…
1 3
International Network for the Study of HIV-associated 
IRIS (INSHI) [11, 12] for defining IRIS events. In brief, 
paradoxical IRIS was defined as a clinical worsening of a 
known and adequately treated pre-existing infection with 
response to ART, in the absence of drug resistance or side 
effects of drugs used; unmasking IRIS was defined as an 
exaggerated local or systemic inflammation as a result 
of an undiagnosed condition, soon after the commence-
ment of ART. Each suspected case was discussed by three 
investigators (SJ, KO and MPG). Information on mortal-
ity was supplemented using the HIV clinic’s register for 
deceased patients.
In case of a delayed clinic visit, multiple phone calls 
were made to urge the patient to attend the clinic. Loss to 
follow-up was defined as a patient delaying clinic visits of 
more than 2 weeks. Non-compliance was defined as a self-
reported interruption of ART for at least 2 weeks.
All clinical visits were performed by one of the two 
study physicians (SJ and KO); patients were seen by 
the same physician at subsequent visits in most cases to 
reduce inter-observer bias. Patients were supported with 
a reimbursement of transport costs to reduce barriers to 
coming to the clinic outside of scheduled visits in case of 
deterioration.
We compared patients by IRIS and survival status. To 
evaluate selection bias, we compared patients included 
in the primary analysis with those, who became LTFU or 
were excluded due to non-compliance. Data were assessed 
for completeness. If for a certain factor >10% of data were 
missing, patient characteristics for the group with missing 
data were compared to those with complete data.
Patient groups were compared using Fisher’s exact test 
for categorical data and Mann–Whitney U test for con-
tinuous data. Kaplan–Meier curves were used to calculate 
the cumulative incidence of IRIS and six month mortal-
ity using percentages and 95% confidence intervals. Log-
rank tests were applied to examine associations between 
baseline characteristics and time to IRIS event or mortal-
ity. Patients LTFU or excluded because of non-compliance 
were censored. We used SPSS Statistics Version 21 (IBM, 
Chicago, IL, USA) and GraphPad PRISM Version 6 (San 
Diego, CA, USA).
Results
From February 2012 to November 2013, 386 HIV-infected 
patients were screened; 104 individuals were recruited, 
Fig. 1  Study flow. Figure showing the study flow from screening to 
enrolment and follow-up. Twenty-seven patients were diagnosed with 
one or more opportunistic infections at enrolment. 1Focused Assess-
ment with Sonography for HIV-associated TB (FASH), 2Serum cryp-
tococcal latex antigen test (serum CLAT), 3human T-cell lympho-
tropic virus 1 (HTLV-1)
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of which 101 were included in the final analysis (Fig. 1). 
Twenty-seven patients were diagnosed with one or more 
opportunistic infections at enrolment; 20 patients were 
diagnosed with active TB; 13/20 had pulmonary TB, 7/20 
had extrapulmonary manifestations. TB was microbiologi-
cally confirmed in 6/20 patients. All of them started TB 
treatment before ART initiation. Furthermore, one patient 
was diagnosed with Kaposi sarcoma, three patients had 
oral candidiasis, two were diagnosed with Herpes zoster 
reactivation, one had both oral candidiasis and Herpes zos-
ter reactivation, and two had oral candidiasis and pulmo-
nary TB (Fig. 1). Eighty-five patients initiated ART within 
one week of enrolment. The remaining 16 patients started 
ART after a median of 26 days (interquartile range (IQR) 
9–42 days), due to diagnosis of opportunistic infections at 
study inclusion, or non-compliance.
Baseline characteristics of the study population are 
shown in the Table 1. Most participants were female, on 
Table 1  Patient characteristics at baseline and follow-up
Patient characteristics for the total cohort; patients who developed IRIS and patients who deceased during the study follow-up
BMI Body mass index, WHO World Health Organization, TB Tuberculosis, HTLV-1 Human T-cell lymphotropic virus-1
1 Patients who developed IRIS versus those who did not
2 Patients who deceased within the study period versus those who survived
Data (n = 101) Total cohort (n = 101) IRIS cases (n = 5) p value1 Deceased (n = 6) p value2
Male sex (N,  %) 101 34 (33.7) 1 (20.0) 0.66 1 (16.7) 0.66
Age (median, IQR) 101 38 (31–47) 41 (36–48) 0.37 47 (34–57) 0.15
BMI (kg/m2) 96 20.9 (18.6–23.4) 18.7 (18.2–22.6) 0.31 19.7 (16.4–21.3) 0.17
WHO stage (n,  %) 101 0.02 0.08
 1 39 (38.6) 0 (0) 1 (16.7)
 2 18 (17.8) 0 (0) 0 (0)
 3 27 (26.7) 3 (60.0) 3 (50)
  4 17 (16.8) 2 (40.0) 2 (33.3)
Baseline co-infections 101
 TB 101 20 (19.8) 3 (60) 0.05 3 (50) 0.09
 Herpes zoster 101 3 (3.0) 0 (0) 0.81 0 (0) 0.45
 Kaposi sarcoma 101 1 (1.0) 0 (0) 0.81 0 (0) 0.45
 Candidiasis or dermatomycosis 101 6 (5.9) 1 (20.0) 0.81 0 (0) 0.45
 Hepatitis B 97 3 (3.1) 0 (0) 0.85 0 (0) 0.82
 Cryptococcosis 93 2 (2.2) 0 (0) 0.90 0 (0) 0.89
 HTLV-1 101 4 (4.0) 0 (0) 0.81 0 (0) 0.78
Laboratory diagnostics
 Hemoglobin (g/dL) 97 10.1 (8.6–12.2) 8.3 (7.1–10.0) 0.06 6.2 (5.6–9.3) 0.008
 White cell count (*10e9/L) 96 4.1 (3.3–5.3) 4.1 (3.8–6.0) 0.47 5.3 (2.9–6.2) 0.49
 Neutrophils (*10e9/L) 71 1.73 (1.26–2.38) 2.02 (1.30–2.38) 0.72 1.78 (1.11–3.73) 0.85
 Lymphocytes (*10e9/L) 76 1.29 (0.97–1.77) 1.12 (0.81–2.65) 0.95 1.46 (0.64–2.17) 0.75
 Monocytes (*10e9/L) 76 0.48 (0.37–0.67) 0.72 (0.42–0.99) 0.30 0.62 (0.47–1.10) 0.20
 Eosinophils (*10e9/L) 83 0.19 (0.08–0.50) 0.04 (0.02–0.07) 0.009 0.20 (0.09–0.43) 0.82
 Eosinophilia (n,  %) 65 18 (28.6) 0 (0) 0.55 1 (25) 0.68
 Platelets (*10e9/L) 96 216 (159–289) 296 (199–318) 0.16 191 (145–233) 0.43
 HIV viral load (log copies/mL) 84 4.87 (4.37–5.34) 5.16 (3.19–5.69) 0.68 5.43 (4.97–5.76) 0.06
 CD4 count (cells/µL) 101 180 (69–252) 26 (13–170) 0.04 165 (108–237) 0.97
 CD8 count (cells/µL) 92 768 (514–1227) 580 (403–1000) 0.31 597 (352–1525) 0.52
 Creatinine (mmol/L) 96 59 (45–72) 64 (44–91) 0.61 52 (44–108) 1.00
Immunologic response
 Total CD4 increase during study period 
(cells/µL)
64 155 (49–262) 230 (78–303) 0.45 ND ND
 Viral load undetectable month 3 (n,  %) 35 27 (77.1) 2 (50) 0.77 ND ND
 Viral load undetectable month 6 (n,  %) 26 19 (73.1) ND ND ND ND
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average 38 years of age. Most patients presented in an 
asymptomatic stage; although 44/101 (43.5%) presented 
with WHO stage 3 or 4. The median CD4 count at pres-
entation was 180 (IQR 69-252) cells/uL. Eosinophilia 
(>0.45 × 109 cells/L) was common (18/65 (28.6%) of 
patients at baseline).
Of 101 included patients, 14 were excluded due to non-
compliance; 21 were LTFU and six died. Sixty patients 
completed the six month follow-up period. Eight patients 
(8/101, 7.9%) developed a suspected IRIS event. After 
reviewing clinical information, one case was defined as 
ART-associated TB rather than IRIS as there was no exag-
gerated inflammation, and two were defined as non-IRIS 
events due to a lack of evidence of immune reconstitu-
tion, as defined as lack of CD4 count increase and HIV 
viral load decline at the time of the event. IRIS was diag-
nosed in five cases (5/101; 5.0%), leading to a cumula-
tive incidence of 6% (95% CI 0.7–12). Four patients had 
unmasking mucocutaneous manifestations of IRIS with 
new KS lesions in one patient, molluscum contagiosum in 
two patients and dermatomycosis in the last (prevalence 
unmasking mucocutaneous IRIS 4/92 patients without 
signs of mucocutaneous infections at baseline; 4%). Of 
nine patients presenting with mucocutaneous infection at 
baseline, one patient developed a paradoxical worsening of 
an ophthalmic manifestation, with worsening of skin erup-
tions and a decrease in visual acuity (prevalence paradoxi-
cal mucocutaneous IRIS 1/9; 11%). None of the patients 
diagnosed with active TB at baseline developed paradoxi-
cal TB-IRIS, and there were no unmasking TB-IRIS cases. 
The five IRIS events developed at a median of 44 (range 
19–113) days after initiation of ART, and resolved with 
supportive care and continuation of ART. None of the 
patients died as a consequence of IRIS. Treatment with 
steroids or hospitalization was not required.
Patients who developed IRIS presented more often with 
a symptomatic WHO stage compared to patients who did 
not, had lower baseline CD4 counts, lower eosinophil 
counts and were more often diagnosed with active TB at 
baseline (Table 1). Only diagnosis of active TB at enrol-
ment was associated with developing IRIS (p = 0.02) 
(Fig. 2).
Six patients (6/101, 6%; cumulative incidence 8%, 95% 
CI 7–8) died after a median of 68 (range 13–144) days. TB 
was diagnosed in three of them at enrolment; no additional 
information on the cause of death was available. Patients 
who died had lower hemoglobin concentrations compared 
to those who survived (Table 1). Lower concentrations of 
hemoglobin (p = 0.03) and diagnosis of active TB at enrol-
ment (p = 0.02) were associated with time to mortality 
(Fig. 2a, b).
To assess selection bias, we compared baseline demo-
graphics and clinical data for patients who completed the 
6-month follow-up period to those data for patients who 
were either LTFU or excluded because of non-compliance 
(Supplementary Table). There were three HTLV1 confected 
patients who were all in the non-compliant group. No fur-
ther differences were detected. For the variables HIV viral 
load and eosinophil counts, there were more than 10% of 
data missing (Table 1). To assess for bias related to missing 
data, baseline demographics and clinical data for patients 
with missing values were compared to those with complete 
values. No significant differences were found (data not 
shown).
Discussion
This study reports on the occurrence of IRIS and early 
mortality after starting ART in a primary HIV care setting 
in Gabon. Main findings were the low incidence of IRIS 
and the relatively mild manifestations of the syndrome. On 
the contrary, mortality during the first 6 months after ART 
initiation was moderately high.
The cumulative incidence of IRIS was 6%, which is 
relatively low compared to other low and middle income 
settings with a high burden of HIV and TB [1, 13]. Most 
cases where unmasking mucocutaneous manifestations, 
which were relatively mild and resolved with topical treat-
ment and continuation of ART. Although we do report one 
case of ART-associated TB, no unmasking or paradoxical 
TB IRIS cases were seen. Our data on the incidence of 
unmasking TB IRIS are in line with previous reports from 
equatorial settings [14, 15].
Diagnosis of active TB at baseline was associated with 
the development of IRIS. Although no cases of TB IRIS are 
reported; in this case, TB might be an indicator of advanced 
HIV at baseline, and thus a higher risk to develop IRIS. 
Patients who developed IRIS presented with lower nadir 
CD4 counts. Both risk factors have been reported before [1, 
13], supporting the generalizability of our findings.
We report a moderately high mortality in the first six 
months after starting ART, with TB being the major risk 
factor. High early mortality after initiation of ART, particu-
larly in TB patients, is an emerging challenge in many set-
tings, and recently this topic was placed high on the global 
research agenda [16].
There are several explanations for the low incidence 
of IRIS in this equatorial setting. Our patients under-
went a thorough work-up for opportunistic infections 
before ART initiation, including a FASH ultrasound, 
potentially preventing unmasking cases. Our patients 
presented on average with higher nadir CD4 counts com-
pared to cohorts from certain other settings, like Mozam-
bique, South Africa and Uganda [15, 17, 18]. However, 
there is a tendency towards a lower reported incidence 
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of unmasking IRIS in equatorial settings [13], maybe 
due to a lack of access to diagnostics for opportunistic 
infections, or due to a biological phenomenon, like a low 
prevalence of vitamin D deficiency or a high rate of hel-
minthic co-infections.
Our study is limited by the high rate of LTFU and non-
compliance to ART. This finding has been reported in this 
particular setting before [19], and is a major threat to the 
functioning of HIV programs in Africa. Cases of IRIS 
might have been missed, although this risk was reduced 
Fig. 2  Time to death or IRIS, TB status and baseline hemoglobin. a 
is showing the cumulative survival after initiation of ART in patients 
with (red line) or without (blue line) diagnosis of active TB at enrol-
ment. Diagnosis of active TB at enrolment was associated with mor-
tality (p = 0.02). b is showing the cumulative survival after initia-
tion of ART in patients with hemoglobin concentrations above (blue 
line) or below (green line) the median concentration of 10.1 g/dL. 
Lower hemoglobin concentrations were associated with mortality 
(p = 0.03). c showing the cumulative survival without IRIS after ini-
tiation of ART in patients with (red line) or without (blue line) diag-
nosis of active TB at enrolment. Diagnosis of active TB at enrolment 
was associated with development of IRIS (p = 0.02)
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by facilitating presentation to the clinic by refunding 
travel fees. Multivariate regression analysis of factors 
associated with development of IRIS or mortality was 
not possible, due to a low number of events. According 
to prevalences found in previous studies [1], we expected 
to detect at least 30 cases of IRIS, which would have 
allowed for this kind of statistical analysis. Our study is 
underpowered to draw reliable conclusions on the occur-
rence of paradoxical TB and cryptococcal IRIS. No reli-
able data were available on the cause of death of our 
patients. These patients died at home or at other hospi-
tals; none of them died at the HIV clinic. Therefore, in 
this setting with low resources and poor infrastructure, it 
was not possible to obtain reliable information on death 
causality.
Important strengths of our study are the prospective 
design and the thorough work-up of our patients to facili-
tate diagnosis of opportunistic infections and manifesta-
tions of IRIS. Baseline and follow-up visits were done by 
the same physician in most instances in order to minimize 
inter-observer bias and the misrecognition of IRIS events. 
All suspected cases were discussed by the study team to 
verify consistency with international definitions [11, 12].
This study represents pioneering work in this setting 
as there is very limited information published on the HIV 
and TB epidemic in Gabon [10, 19–21]. The occurrence of 
drug-resistant TB in this setting has only recently been rec-
ognized [10], and limited information has been reported on 
treatment outcomes in HIV or TB cohorts.
In conclusion, we report a low incidence of IRIS in 
Gabon with relatively mild manifestations. Further research 
on IRIS in equatorial settings is needed, to confirm this low 
incidence and to elucidate potential causative factors that 
may inform strategies to prevent the development of IRIS 
in high prevalence settings.
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